Q-omics provides the consensus-scored MAFG profile across patient tissues and cancer cell-line models. MAFG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MAFG is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, MAFG RNA expression shows 20,010 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, COAD, and ACC as cancer lineages where MAFG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAFG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAFG survival associations across molecular data types. MAFG RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAFG RNA expression–survival associations across cancer types. High MAFG expression shows unfavorable associations in LIHC, COAD, BLCA, HNSC, ACC and ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MAFG RNA expression.
This table summarizes MAFG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MAFG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAFG shows lower tumor expression in THCA and higher tumor expression in COAD, KIRP, HNSC, LIHC and KIRC. The COAD box plot shows higher MAFG RNA expression in tumor versus normal tissue (log2 FC = +1.070, t-test p < 0.001).
This table shows molecular features associated with MAFG in patient tissues and cancer cell lines. In patient samples, MAFG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAFG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
